Type 2 Diabetes Market By Treatment (Drug (Insulin, Sensitizers, Sglt-2, Alpha-Glucosidase Inhibitors, Others), Devices (Blood Glucose Monitoring, Insulin Delivery Devices); By Region (U.S., Canada, Mexico, Rest of North America, UK, France, Germany, Italy, Spain, Benelux Union, Nordic Countries , Rest of Europe, China, Japan, India, South Korea, Australia, New Zealand, Southeast Asia, Rest of Asia Pacific Brazil, Argentina Rest of Latin America, GCC countries, Southern Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global Type 2 Diabetes market was estimated to be US$ 33407.97 million in 2018 and is expected to reach US$ 58758.9 million by 2027, growing at an estimated CAGR of 6.5% over the forecast period. The main cause of Type 2 diabetes market is the lack of physical activity in one’s life and excess body weight. The global market for diabetes care is experiencing a major transition, powered by the advent of new analytical techniques and diabetes treatment advances. Due to the rising rates of sedentary lifestyles and obesity among the global population, there has been a drastic increase in diabetes incidents worldwide. It is expected that the submarkets such as human insulin and analogues will retain dominance in the overall market for diabetes treatment. Type 2 diabetes mellitus is a metabolic disorder that results from excess caloric intake. The condition is characterized by a progressive insulin secretory deficiency which increases the body's demand for insulin to maintain homeostasis of glucose. Hyperglycemia is a significant symptom of type 2 mellitus diabetes. It is noted that the key factors driving the Type 2 diabetes market are increasing technological advances and escalating prevalence. It has been recently noted that this type of diabetes was not only seen in adults but also seen increasingly in children.
With the growing awareness of the disease coupled with technological advances, industry players are coming up with innovative drugs and tools. Numerous other factors, such as increased awareness, research funding for diabetes diagnosis and treatment, unmet medical needs, global prevalence of obesity, strict regulatory framework, increased government assistance and increased adoption rates, are continually contributing to the growth of the global market for Type 2 diabetes. Given these drivers, there are some issues surrounding the demand for diabetes type 2 care. The high cost of diagnosing and treating diabetes, the side effects of available treatment options and the poor healthcare system in low-and middle-income countries is expected to critically impact the overall market growth. It has been recently reported that the annual incidence of Type 2 diabetes is 5.2% in the United States. Since the disease type is progressive in nature, the drugs tend to have good effect amongst the treatment options and also controls the blood sugar levels. Sometimes after a specific duration the drugs tend to lose efficacy even with higher doses of the same medications. Moreover, many patients continue to have uncontrolled diabetes, so they require new treatment options with improved durability, safety profiles, and impact on non-insulin parameters such as lipids, weight, and blood pressure. Such type of new drugs should be formulated on the basis of the requirement. Some of the drugs prescribed for type 2 diabetes are as follows:
Metformin- This is a first prescribed drug for type 2 diabetes treatment. It generally works by lowering the glucose production in the liver and also improves the body's sensitivity to insulin, such that the body uses insulin more effectively. Common side effects of this type is diarrhoea and nausea.
Sulfonylureas – These medications help the body to secrete more insulin. Some of the instances include, glyburide (DiaBeta, Glynase), glimepiride (Amaryl) and glipizide (Glucotrol). Side effects of the same includes weight gain and low blood sugar levels.
Meglitinides – Medications such as nateglinide (Starlix) and repaglinide (Prandin) work similar to sulfonylureas by stimulating the pancreas to create more insulin. Side-effects of the same consists of weight gain and increased risk of heart failure and anaemia. Such medications are not considered the first choice of treatment.
New insulin delivery systems are being developed to treat both hyperglycemia and hypoglycaemia and to increase efficacy while reducing diabetes care problems in the future. Valeritas, Inc comes with new advanced insulin delivery system under the brand name V-Go. It is simple and a disposable device for the insulin therapy for type 2 diabetes patients. V-Go provides pre-set, sustained release of insulin as per the body’s requirement. It is the best alternative for the multiple daily insulin injections. It is small, light in weight like a patch and patients have to apply on the skin after filling proper amount of insulin into it. High cost of diagnosis and treatment is restraining the type 2 diabetes market growth. According to a report published by American Diabetes Association, diabetes was estimated to be the most costly disease in the United States in 2017. The report also shows that the cost related to diabetes has increased by 26 percent from 2012 to 2017. Moreover, the overall cost includes, diagnostic cost which is approximately calculated to be $90 billion, prescription diabetes medications cost was $71.2 billion, hospital inpatients services cost was $ 69.7 billion and other medicines cost was $34.6 billion. According to the American Disease Association, the average price of insulin approximately increased by four times of the base price between 2002 and 2015.
The research and development for diabetes drugs is expected to propel the growth of the overall market in the future years. As discussed previously, many type of drugs like sulfonylureas, meglitinides, thiazides and biguanides are available as a treatment option for the type 2 diabetes. But not a single drug is available to completely cure diabetes. In addition, the long term use of these drugs shows side effects and complications in the body and ultimately produces cardiovascular complications, liver diseases, kidney diseases and weight gain. As many of the drugs shows interference and interaction after administration, anti-diabetic drugs also show interference and interaction with other drugs, if the patient is taking them for a long time. According to a new study published by researchers in Weill Cornell Medicine and NewYork-Presbyterian, the protein adipsin which is produced in body fat helps in protecting the insulin-secreting cells named as pancreatic beta cells from destruction in Type 2 diabetes disease. The same was recently published in November, 2019. Also, amongst the middle-aged adults, higher levels of the protein in the blood were also associated with protection from type 2 diabetes. The researchers were well-versed about the fact that adipsin had a role in stimulating beta cells to secrete insulin. Thus, they eventually theorized that this could be a potential therapy for type 2 diabetes treatment. Such a factor is expected to aid the overall type 2 diabetes market over the next eight years.
By Treatment + Devices
The treatment segment captured the highest share in 2018 and is expected to continue the same trend over the forecast period. The advent of new medications and shifting focus from injectable to oral medications will lead the aforementioned segment growth. Also, in September 2019, the United States Food and Drug Administration approved the intake of a new pill to lower blood sugar levels for people suffering from Type 2 Diabetes. The drug named Rybelsus (semaglutide) is the first pill in a class of drugs called glucagon-like peptide (GLP-1) approved for use in the United States. Before this, the medication was injected. The medicine acts by slowing digestion and prevent the liver from secreting high level of sugar, which in turn helps the pancreas produce more insulin.
Regional Insights
Due to the presence of patient population, well-developed infrastructure, high healthcare spending, and the presence of leading players, the North America dominated the Type 2 diabetes market. Due to the increasing incidence of diabetes, numerous organizations and governmental bodies are actively involved in the development of diabetes care. Europe holds second place in the market for diabetes type 2 care. It is expected that government support to spending on research & development and improvements in healthcare reimbursement policies will likely drive the European market.
Type 2 Diabetes Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of Type 2 diabetes market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
The key players Type 2 Diabetes Market include Abbott Laboratories, Acon Laboratories, Inc., Adocia, Akros Pharma, Amgen, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck, Novartis Co., Novo Nordisk, Peptron, Pfizer, Roche Diagnostics Ltd., Sanofi, Sunpharma, Takeda Pharmaceuticals amongst others.
Type 2 Diabetes Market:
- By Treatment + Devices
- Treatment
- Drug
- Alpha-Glucosidase Inhibitors
- Others
- Devices
- Blood Glucose Monitoring
- Insulin Delivery Devices
- Treatment
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Type 2 Diabetes Market
6. Market Synopsis: Type
2 Diabetes Market
7. Type 2 Diabetes Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Type 2 Diabetes Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Type 2 Diabetes Market
7.6. Industry
Gross Margin Overview
7.7. Porter’s
Five Force Analysis
8. Global Type 2 Diabetes Market Analysis and Forecasts, 2019 –
2027
8.1. Overview
8.1.1. Global
Type 2 Diabetes Market Revenue (US$ Mn)
8.2. Global
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
8.2.1. Drug
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Alpha-Glucosidase
Inhibitors
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Others
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Treatment
9. Global Type 2 Diabetes Market Analysis and Forecasts, 2019 –
2027
9.1. Overview
9.2. Global
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
9.2.1. Blood
Glucose Monitoring
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Insulin
Delivery Devices
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Devices
10. North America Type 2 Diabetes Market Analysis and Forecasts,
2019 - 2027
10.1. Overview
10.1.1. North
America Type 2 Diabetes Market Revenue (US$ Mn)
10.2. North
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.1. Drug
10.2.2. Alpha-Glucosidase
Inhibitors
10.2.3. Others
10.3. North
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
10.3.1. Blood
Glucose Monitoring
10.3.2. Insulin
Delivery Devices
10.4. North
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
10.4.1.1.1. Drug
10.4.1.1.2. Alpha-Glucosidase
Inhibitors
10.4.1.1.3. Others
10.4.1.2. U.S
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
10.4.1.2.1. Blood
Glucose Monitoring
10.4.1.2.2. Insulin
Delivery Devices
10.4.2. Canada
10.4.2.1. Canada
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
10.4.2.1.1. Drug
10.4.2.1.2. Alpha-Glucosidase
Inhibitors
10.4.2.1.3. Others
10.4.2.2. Canada
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
10.4.2.2.1. Blood
Glucose Monitoring
10.4.2.2.2. Insulin
Delivery Devices
10.4.3. Mexico
10.4.3.1. Mexico
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
10.4.3.1.1. Drug
10.4.3.1.2. Alpha-Glucosidase
Inhibitors
10.4.3.1.3. Others
10.4.3.2. Mexico
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
10.4.3.2.1. Blood
Glucose Monitoring
10.4.3.2.2. Insulin
Delivery Devices
10.4.4. Rest of
North America
10.4.4.1. Rest
of North America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Treatment
10.4.4.1.1. Drug
10.4.4.1.2. Alpha-Glucosidase
Inhibitors
10.4.4.1.3. Others
10.4.4.2. Rest
of North America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Devices
10.4.4.2.1. Blood
Glucose Monitoring
10.4.4.2.2. Insulin
Delivery Devices
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Treatment
10.5.3. By
Devices
11. Europe Type 2 Diabetes Market Analysis and Forecasts, 2019 -
2027
11.1. Overview
11.1.1. Europe
Type 2 Diabetes Market Revenue (US$ Mn)
11.2. Europe
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.2.1. Drug
11.2.2. Alpha-Glucosidase
Inhibitors
11.2.3. Others
11.3. Europe
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.3.1. Blood
Glucose Monitoring
11.3.2. Insulin
Delivery Devices
11.4. Europe
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.1.1.1. Drug
11.4.1.1.2. Alpha-Glucosidase
Inhibitors
11.4.1.1.3. Others
11.4.1.2. France
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.1.2.1. Blood
Glucose Monitoring
11.4.1.2.2. Insulin
Delivery Devices
11.4.2. The UK
11.4.2.1. The
UK Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.2.1.1. Drug
11.4.2.1.2. Alpha-Glucosidase
Inhibitors
11.4.2.1.3. Others
11.4.2.2. The
UK Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.2.2.1. Blood
Glucose Monitoring
11.4.2.2.2. Insulin
Delivery Devices
11.4.3. Spain
11.4.3.1. Spain
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.3.1.1. Drug
11.4.3.1.2. Alpha-Glucosidase
Inhibitors
11.4.3.1.3. Others
11.4.3.2. Spain
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.3.2.1. Blood
Glucose Monitoring
11.4.3.2.2. Insulin
Delivery Devices
11.4.4. Germany
11.4.4.1. Germany
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.4.1.1. Drug
11.4.4.1.2. Alpha-Glucosidase
Inhibitors
11.4.4.1.3. Others
11.4.4.2. Germany
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.4.2.1. Blood
Glucose Monitoring
11.4.4.2.2. Insulin
Delivery Devices
11.4.5. Italy
11.4.5.1. Italy
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.5.1.1. Drug
11.4.5.1.2. Alpha-Glucosidase
Inhibitors
11.4.5.1.3. Others
11.4.5.2. Italy
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.5.2.1. Blood
Glucose Monitoring
11.4.5.2.2. Insulin
Delivery Devices
11.4.6. Nordic
Countries
11.4.6.1. Nordic
Countries Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.6.1.1. Drug
11.4.6.1.2. Alpha-Glucosidase
Inhibitors
11.4.6.1.3. Others
11.4.6.2. Nordic
Countries Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.6.2.1. Blood
Glucose Monitoring
11.4.6.2.2. Insulin
Delivery Devices
11.4.6.3. Nordic
Countries Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux
Union Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.7.1.1. Drug
11.4.7.1.2. Alpha-Glucosidase
Inhibitors
11.4.7.1.3. Others
11.4.7.2. Benelux
Union Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.7.2.1. Blood
Glucose Monitoring
11.4.7.2.2. Insulin
Delivery Devices
11.4.7.3. Benelux
Union Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest
of Europe Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
11.4.8.1.1. Drug
11.4.8.1.2. Alpha-Glucosidase
Inhibitors
11.4.8.1.3. Others
11.4.8.2. Rest
of Europe Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
11.4.8.2.1. Blood
Glucose Monitoring
11.4.8.2.2. Insulin
Delivery Devices
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Treatment
11.5.3. By
Devices
12. Asia Pacific Type 2 Diabetes Market Analysis and Forecasts,
2019 - 2027
12.1. Overview
12.1.1. Asia
Pacific Type 2 Diabetes Market Revenue (US$ Mn)
12.2. Asia
Pacific Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.2.1. Drug
12.2.2. Alpha-Glucosidase
Inhibitors
12.2.3. Others
12.3. Asia
Pacific Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.3.1. Blood
Glucose Monitoring
12.3.2. Insulin
Delivery Devices
12.4. Asia
Pacific Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.1.1.1. Drug
12.4.1.1.2. Alpha-Glucosidase
Inhibitors
12.4.1.1.3. Others
12.4.1.2. China
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.1.2.1. Blood
Glucose Monitoring
12.4.1.2.2. Insulin
Delivery Devices
12.4.2. Japan
12.4.2.1. Japan
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.2.1.1. Drug
12.4.2.1.2. Alpha-Glucosidase
Inhibitors
12.4.2.1.3. Others
12.4.2.2. Japan
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.2.2.1. Blood
Glucose Monitoring
12.4.2.2.2. Insulin
Delivery Devices
12.4.3. India
12.4.3.1. India
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.3.1.1. Drug
12.4.3.1.2. Alpha-Glucosidase
Inhibitors
12.4.3.1.3. Others
12.4.3.2. India
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.3.2.1. Blood
Glucose Monitoring
12.4.3.2.2. Insulin
Delivery Devices
12.4.4. New
Zealand
12.4.4.1. New
Zealand Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.4.1.1. Drug
12.4.4.1.2. Alpha-Glucosidase
Inhibitors
12.4.4.1.3. Others
12.4.4.2. New
Zealand Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.4.2.1. Blood
Glucose Monitoring
12.4.4.2.2. Insulin
Delivery Devices
12.4.5. Australia
12.4.5.1. Australia
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.5.1.1. Drug
12.4.5.1.2. Alpha-Glucosidase
Inhibitors
12.4.5.1.3. Others
12.4.5.2. Australia
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.5.2.1. Blood
Glucose Monitoring
12.4.5.2.2. Insulin
Delivery Devices
12.4.6. South
Korea
12.4.6.1. South
Korea Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.6.1.1. Drug
12.4.6.1.2. Alpha-Glucosidase
Inhibitors
12.4.6.1.3. Others
12.4.6.2. South
Korea Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.6.2.1. Blood
Glucose Monitoring
12.4.6.2.2. Insulin
Delivery Devices
12.4.7. Southeast
Asia
12.4.7.1. Southeast
Asia Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
12.4.7.1.1. Drug
12.4.7.1.2. Alpha-Glucosidase
Inhibitors
12.4.7.1.3. Others
12.4.7.2. Southeast
Asia Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
12.4.7.2.1. Blood
Glucose Monitoring
12.4.7.2.2. Insulin
Delivery Devices
12.4.7.3. Southeast
Asia Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest
of Asia Pacific Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Treatment
12.4.8.1.1. Drug
12.4.8.1.2. Alpha-Glucosidase
Inhibitors
12.4.8.1.3. Others
12.4.8.2. Rest
of Asia Pacific Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Devices
12.4.8.2.1. Blood
Glucose Monitoring
12.4.8.2.2. Insulin
Delivery Devices
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Treatment
12.5.3. By
Devices
13. Middle East and Africa Type 2 Diabetes Market Analysis and
Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle
East and Africa Type 2 Diabetes Market Revenue (US$ Mn)
13.2. Middle
East and Africa Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Treatment
13.2.1. Drug
13.2.2. Alpha-Glucosidase
Inhibitors
13.2.3. Others
13.3. Middle
East and Africa Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Devices
13.3.1. Blood
Glucose Monitoring
13.3.2. Insulin
Delivery Devices
13.4. Middle
East and Africa Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi
Arabia Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
13.4.1.1.1. Drug
13.4.1.1.2. Alpha-Glucosidase
Inhibitors
13.4.1.1.3. Others
13.4.1.2. Saudi
Arabia Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
13.4.1.2.1. Blood
Glucose Monitoring
13.4.1.2.2. Insulin
Delivery Devices
13.4.2. UAE
13.4.2.1. UAE
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
13.4.2.1.1. Drug
13.4.2.1.2. Alpha-Glucosidase
Inhibitors
13.4.2.1.3. Others
13.4.2.2. UAE
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
13.4.2.2.1. Blood
Glucose Monitoring
13.4.2.2.2. Insulin
Delivery Devices
13.4.3. Egypt
13.4.3.1. Egypt
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
13.4.3.1.1. Drug
13.4.3.1.2. Alpha-Glucosidase
Inhibitors
13.4.3.1.3. Others
13.4.3.2. Egypt
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
13.4.3.2.1. Blood
Glucose Monitoring
13.4.3.2.2. Insulin
Delivery Devices
13.4.4. Kuwait
13.4.4.1. Kuwait
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
13.4.4.1.1. Drug
13.4.4.1.2. Alpha-Glucosidase
Inhibitors
13.4.4.1.3. Others
13.4.4.2. Kuwait
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
13.4.4.2.1. Blood
Glucose Monitoring
13.4.4.2.2. Insulin
Delivery Devices
13.4.5. South
Africa
13.4.5.1. South
Africa Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
13.4.5.1.1. Drug
13.4.5.1.2. Alpha-Glucosidase
Inhibitors
13.4.5.1.3. Others
13.4.5.2. South
Africa Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
13.4.5.2.1. Blood
Glucose Monitoring
13.4.5.2.2. Insulin
Delivery Devices
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest
of Middle East & Africa Type 2 Diabetes Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.6.1.1. Drug
13.4.6.1.2. Alpha-Glucosidase
Inhibitors
13.4.6.1.3. Others
13.4.6.2. Rest
of Middle East & Africa Type 2 Diabetes Market Revenue (US$ Mn) and
Forecasts, By Devices
13.4.6.2.1. Blood
Glucose Monitoring
13.4.6.2.2. Insulin
Delivery Devices
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Treatment
13.5.3. By
Devices
14. Latin America Type 2 Diabetes Market Analysis and Forecasts,
2019 - 2027
14.1. Overview
14.1.1. Latin
America Type 2 Diabetes Market Revenue (US$ Mn)
14.2. Latin
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
14.2.1. Drug
14.2.2. Alpha-Glucosidase
Inhibitors
14.2.3. Others
14.3. Latin
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
14.3.1. Blood
Glucose Monitoring
14.3.2. Insulin
Delivery Devices
14.4. Latin
America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
14.4.1.1.1. Drug
14.4.1.1.2. Alpha-Glucosidase
Inhibitors
14.4.1.1.3. Others
14.4.1.2. Brazil
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
14.4.1.2.1. Blood
Glucose Monitoring
14.4.1.2.2. Insulin
Delivery Devices
14.4.2. Argentina
14.4.2.1. Argentina
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Treatment
14.4.2.1.1. Drug
14.4.2.1.2. Alpha-Glucosidase
Inhibitors
14.4.2.1.3. Others
14.4.2.2. Argentina
Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By Devices
14.4.2.2.1. Blood
Glucose Monitoring
14.4.2.2.2. Insulin
Delivery Devices
14.4.3. Rest of
Latin America
14.4.3.1. Rest
of Latin America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.4.3.1.1. Drug
14.4.3.1.2. Alpha-Glucosidase
Inhibitors
14.4.3.1.3. Others
14.4.3.2. Rest
of Latin America Type 2 Diabetes Market Revenue (US$ Mn) and Forecasts, By
Devices
14.4.3.2.1. Blood
Glucose Monitoring
14.4.3.2.2. Insulin
Delivery Devices
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Treatment
14.5.3. By
Devices
15. Competitive Benchmarking
15.1. Market
Share Analysis, 2018
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player Profiles
16.1. Abbott
Laboratories
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. Acon
Laboratories, Inc.
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. Adocia
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Akros
Pharma
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. Amgen
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Astra
Zeneca
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Bayer AG
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. Becton
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Biocon
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Boehringer
Ingelheim
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. Daiichi
Sankyo
16.11.1. Company
Details
16.11.2. Company
Overview
16.11.3. Product
Offerings
16.11.4. Key
Developments
16.11.5. Financial
Analysis
16.11.6. SWOT
Analysis
16.11.7. Business
Strategies
16.12. Eli
Lilly
16.12.1. Company
Details
16.12.2. Company
Overview
16.12.3. Product
Offerings
16.12.4. Key
Developments
16.12.5. Financial
Analysis
16.12.6. SWOT
Analysis
16.12.7. Business
Strategies
16.13. Merck
16.13.1. Company
Details
16.13.2. Company
Overview
16.13.3. Product
Offerings
16.13.4. Key
Developments
16.13.5. Financial
Analysis
16.13.6. SWOT
Analysis
16.13.7. Business
Strategies
16.14. Novartis
Co.
16.14.1. Company
Details
16.14.2. Company
Overview
16.14.3. Product
Offerings
16.14.4. Key
Developments
16.14.5. Financial
Analysis
16.14.6. SWOT
Analysis
16.14.7. Business
Strategies
16.15. Novo
Nordisk
16.15.1. Company
Details
16.15.2. Company
Overview
16.15.3. Product
Offerings
16.15.4. Key
Developments
16.15.5. Financial
Analysis
16.15.6. SWOT
Analysis
16.15.7. Business
Strategies
16.16. Peptron
16.16.1. Company
Details
16.16.2. Company
Overview
16.16.3. Product
Offerings
16.16.4. Key
Developments
16.16.5. Financial
Analysis
16.16.6. SWOT
Analysis
16.16.7. Business
Strategies
16.17. Pfizer
16.17.1. Company
Details
16.17.2. Company
Overview
16.17.3. Product
Offerings
16.17.4. Key
Developments
16.17.5. Financial
Analysis
16.17.6. SWOT
Analysis
16.17.7. Business
Strategies
16.18. Other Market Participants.
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.